10x Genomics, Inc.
67.29USD
+1.6900 (+2.58%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 516.4M | 618.7M | 610.8M | 642.8M | 620.4M | 680.0M |
| Q1 | 114.5M | 134.3M | 141.0M | 154.9M | 150.8M | — |
| Q2 | 114.6M | 146.8M | 153.1M | 172.9M | 151.0M | — |
| Q3 | 131.1M | 153.6M | 151.7M | 149.0M | 147.2M | — |
| Q4 | 156.2M* | 184.0M* | 165.0M* | 166.0M* | 171.9M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.46 | -2.18 | -1.52 | -.350 | .105 | .203 |
| Q1 | -.380 | -.440 | -.500 | -.280 | -.100 | — |
| Q2 | -.570 | -.530 | -.320 | .280 | -.140 | — |
| Q3 | -.370 | -.790 | -.300 | -.220 | -.017 | — |
| Q4 | -.151* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.418* |
| -.407* |
| -.130* |
| -.003 |
| — |